SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a surge in investor interest and volatility driven by its strategic shift toward providing behind-the-meter power solutions for the rapidly growing AI data center sector. The community is actively debating the company's recent management cadence, technical breakout potential, and the long-term impact of its ongoing manufacturing expansion versus the persistent risks associated with its historical share dilution.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors rally behind the official launch of the pivotal Phase 3 AURORA trial for NSCLC and anticipation for the prostate cancer BLA submission later this year. The community is actively discussing the stock's significant long-term potential, citing a strong clinical pipeline, a recent strategic C-suite hire, and the expectation that the low float and heavy short interest could drive an explosive upward move.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending due to significant momentum in the 'Physical AI' sector, fueled by its new strategic manufacturing agreement for its REV8 sensor family and recent high-profile infrastructure deployments ahead of the 2026 World Cup. Community sentiment is largely focused on the company's critical role as an enabler for robotics and autonomous systems, with many investors debating whether current price action represents a sustainable breakout for long-term compounding or a high-volatility momentum play.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing significant volatility driven by intense competition from payment giants like Stripe, Visa, and Mastercard entering the stablecoin sector, alongside investor sensitivity to potential regulatory shifts regarding the Clarity Act. The community remains deeply divided, with some investors aggressively accumulating on dips due to long-term conviction in stablecoin adoption, while others are offloading positions amidst concerns over insider selling and weakening price support.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending as it hits new record highs, fueled by intense institutional accumulation and its critical role in wiring high-speed connectivity for AI data center clusters. Community members are actively debating the stock's parabolic move and valuation, with many focused on its inclusion in the Nasdaq-100 and the company's status as a foundational player in the AI infrastructure buildout.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is attracting intense investor attention following a major pivot toward providing power infrastructure for AI data centers, which has triggered aggressive short-covering and bullish sentiment. The community is actively debating the stock's transition from a residential solar play to a broader data-center technology provider, while closely monitoring key resistance levels and insider activity.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing intense momentum as the broader defense and drone sector rallies on expectations of significant government investment in autonomous systems. Investors are aggressively rotating into the stock, fueled by recent earnings-driven volatility and ongoing speculation regarding increased military budget allocations for drone-tech.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors remain focused on the company's long-term growth potential and strong commercial execution, despite ongoing frustration with the stock's recent volatility and persistent legal uncertainty regarding Medicare reimbursement. The community is actively debating the company's path to profitability, the impact of potential competitive entries in the hyperphosphatemia market, and whether the stock's valuation disconnect from analyst targets presents a buying opportunity or a signal of deeper institutional caution.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as shareholders react to a significant selloff following management's commentary on slowing growth for its Watchman franchise, sparking intense community debate over whether this represents a long-term value opportunity or a deeper structural decline. While many investors are actively accumulating shares and positioning for a potential rebound fueled by existing share repurchase programs and solid long-term fundamentals, others remain concerned about mounting technical weakness and the broader rotation of capital into more high-momentum AI sectors.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is garnering significant attention as investors react to its recent inclusion in the Russell index and ongoing community speculation regarding a potential short squeeze driven by high short interest. Market discourse is largely fueled by the broader drone and autonomous defense sector's growth, with bulls pointing to the company's strategic partnerships and government interest as key long-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Average Rating of "Moderate Buy" from Analysts

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. One...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened

Spyglass Pharma (NASDAQ:SGP) Shares Up 8.6% - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Hits New 1-Year Low - What's Next?

Spyglass Pharma (NASDAQ:SGP) Hits New 12-Month Low - Here's Why...

Spyglass Pharma (NASDAQ:SGP) Trading Down 5.2%  - Here's Why

Spyglass Pharma (NASDAQ:SGP) Stock Price Down 5.2% - Time to Sell...

HC Wainwright Lifts Earnings Estimates for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Spyglass Pharma in a report issued on Monday, March 30th...

Spyglass Pharma, Inc. (NASDAQ:SGP) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have issued a...

Spyglass Pharma (NASDAQ:SGP) Cut to "Sell" at Wall Street Zen

Wall Street Zen cut Spyglass Pharma from a "hold" rating to a "sell" rating in a research note on Saturday...

Spyglass Pharma (NASDAQ:SGP) Releases Earnings Results, Beats Expectations By $0.89 EPS

Spyglass Pharma (NASDAQ:SGP - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($5.72) earnings per share (EPS) for the quarter, topping analysts' consensus...

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Time to Buy?

Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.7% - Should You Buy...

Spyglass Pharma (NASDAQ:SGP) Stock Price Down 10.1% - Time to Sell?

Spyglass Pharma (NASDAQ:SGP) Shares Down 10.1% - Here's Why...

SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.

SpyGlass Pharma Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGPSpyGlass Pharma Inc.

Fundamentals

Latest SGP News